A comparative study of two PODXL antibodies in 840 colorectal cancer patients
A comparative study of two PODXL antibodies in 840 colorectal cancer patients
Podocalyxin (PODXL) is a transmembrane sialomucin, whose aberrant expression and/or allelic variation associates with poor prognosis and unfavourable clinicopathological characteristics in different cancers.